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CASE REPORT

Patterns of immunotherapy‑induced
pneumonitis in patients with non‑small‑cell
lung cancer: a case series
Sarah Picard1,2*† , Desiree Goh1,2†, Ashley Tan2,3, Nisha Sikotra3, Eli Gabbay4,5 and Tim Clay2,6,7

Abstract
Background: Immunotherapy has become an efficacious option in the management of solid organ malignancies.
Immune-related adverse events including pneumonitis are well described and may be particularly of concern in
patients receiving immunotherapy for non-small-cell lung cancer.
Case presentations: In this paper, we describe three cases of immunotherapy-induced pneumonitis occurring in
the management of lung malignancy. Our cases include a 54-year-old Caucasian woman with squamous cell lung
cancer who was successfully rechallenged with immunotherapy after prior significant pneumonitis, a 65-year-old
Caucasian man with metastatic squamous cell lung cancer who developed pneumonitis after multiple cycles of
uneventful immunotherapy, and a 73-year-old Caucasian man with squamous cell lung cancer who developed earlyonset pneumonitis with rebound on steroid taper.
Conclusions: This case series has provided further insight into the presentation and risk factors for pneumonitis in
patients with non-small-cell lung cancer. Each of the cases of immunotherapy-induced pneumonitis illustrates the
different potential patterns that may arise when immunotherapy-induced pneumonitis develops. This case series
provides key learning points that may assist physicians managing non-small-cell lung cancer with immunotherapy.
Keywords: Pneumonitis, Immunotherapy, Malignancy, NSCLC, irAE
Background
Immunotherapy is increasingly prescribed for solid organ
and hematological malignancies, with striking improvements in progression-free and overall survival in some
cancers [1]. Immunotherapeutic drugs may cause lifethreatening immune-related adverse events (irAEs)
including pneumonitis, complicating their use in lung
cancer. Patients with advanced non-small-cell lung cancer (NSCLC) have a higher incidence of pneumonitis
from immunotherapy (4.7% incidence) compared with
the overall incidence of pneumonitis in patients with
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other solid organ malignancies receiving immunotherapy
(2.92% incidence) [2]. In this paper, we describe three
cases of immunotherapy-induced pneumonitis occurring
in the management of lung malignancy.
Immune checkpoint inhibitors in routine clinical
practice today target programmed death 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). These pathways
are expressed in normal tissue as a mechanism to control
the immune system, and they can become dysregulated
in the tumor microenvironment [3]. Inhibition of these
proteins with monoclonal antibodies causes upregulation of the immune system [3, 4], allowing it to target
and destroy cancer cells [2, 5]. However, T cells may
also attack noncancerous cells, resulting in irAEs [5, 6]
including pneumonitis.
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Pneumonitis is defined as focal or diffuse inflammation of the lung parenchyma [5, 7–9]. Pneumonitis may
present asymptomatically and be incidentally found on
computerized tomography (CT) scanning, or present
symptomatically with cough, dyspnea, fatigue, or chest
pain or clinical findings of progressive hypoxemia and
respiratory failure [10–12]. Diagnosis is based on appropriate history and suggestive radiological findings on CT
scanning. Definitive diagnosis requires a combination of
bronchoalveolar lavage and/or a biopsy; however, these
investigations are often impractical in an acutely unwell
individual [10–12]. Suggestive radiological features
include ground glass opacities, interstitial reticulation, or
cryptogenic organizing pneumonia-like changes [8-10,
12]. Pneumonitis caused by immunotherapy is graded
using the Common Terminology Criteria for Adverse
Events (CTCAE) severity scale, which ranges from grade
1, asymptomatic, through to grade 5, where death occurs
[2] (Table 1). Initial treatment is often empiric. Treatment options include supportive therapy alone, oral or
intravenous corticosteroids, cessation of immunotherapy,
and, in refractory cases, the use of steroid-sparing agents
as part of prolonged immunosuppression with mycophenolate, infliximab, or cyclophosphamide [11, 13]. The
outcome of patients who develop pneumonitis can range
from complete resolution to death [12, 13].

Case presentations
We present three separate cases of immunotherapy-associated pneumonitis seen at our institution, each of which
we believe has important teaching points, in accordance
with the CARE reporting checklist (Fig. 1).

Case 1: key point—rechallenge with immunotherapy
after prior significant pneumonitis

A 54-year-old Caucasian woman with T3N3M0 stage
IIIB squamous cell lung cancer was initially treated with
induction chemotherapy (carboplatin/paclitaxel) followed by chemoradiotherapy (cisplatin/etoposide) with
curative intent. After 6 months, she relapsed in her primary tumor with increased fluorodeoxyglucose (FDG)
uptake on her positron emission tomography (PET) scan.
She was commenced on the PD-1 inhibitor nivolumab.
She had a prior history of localized cervical cancer, hypothyroidism, and a 6 pack-year smoking history. There
were no other clear risk factors for pneumonitis. Following her first dose of nivolumab, she immediately experienced facial flushing, fever, myalgia, and night sweats.
Nine days following commencement of nivolumab, she
was admitted to hospital with dyspnea.
On admission, her observations were oxygen saturation 80% on room air, heart rate 116 beats per minute,
and respiratory rate 20 breaths per minute. Her CT scan
showed extensive patchy ground-glass infiltrates bilaterally (Fig. 2). She received supplemental oxygen via nasal
prongs. She was commenced on intravenous methylprednisolone 500 mg daily for 4 days followed by a prolonged
taper on oral prednisolone over 3 weeks. She was concurrently treated with intravenous piperacillin–tazobactam and oral trimethoprim/sulfamethoxazole for 6 days
to cover for potential concurrent infection. During her
admission, other causes of pneumonitis were considered
and excluded, and antibiotics ceased. The pneumonitis
was grade 3 as per the Common Terminology Criteria for
Adverse Events (CTCAE) version 5. Upon discharge, her

Table 1 CTCAE grading of pneumonitis with suggested management as per ESMO guidelines
Grade

Clinical features

Management

1

Asymptomatic

Oral steroids—prednisone 1 mg/kg daily or equivalent with taper over
4–6 weeks after recovery
Clinical and assessment every 2–3 days initially
Delay checkpoint inhibitor until equivalent daily dose of 10 mg oral prednisolone or less

2

Symptomatic—limiting instrumental activities of daily living

As per grade 2
AND
Radiological assessment every 2–3 days initially

3

Severe symptoms—limiting self-care activities of daily living

Hospital admission
High-dose intravenous corticosteroids (methylprednisolone 2–4 mg/kg/day or
equivalent)
Cease immunotherapy permanently
Commence immunosuppression if no clinical or imaging improvement after
2 days (such as infliximab, mycophenolate mofetil, cyclophosphamide)
Wean steroids slowly over 6 or more weeks

4

Life-threatening respiratory compromise

As per grade 3

5

Death

CTCAE Common Terminology Criteria for Adverse Events, ESMO European Society for Medical Oncology
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Fig. 1 Timeline of key events

Fig. 2 Case 1—chest computed tomography (CT) revealing signs of
pneumonitis

cardiorespiratory parameters were within normal range,
and she had returned to her premorbid function.
Two months after treatment, the FDG-PET scan
showed an initial partial metabolic response, with
incomplete resolution of the changes due to pneumonitis (Fig. 3). Over time, the pneumonitis settled, but there

Fig. 3 Case 1—CT chest 2 months after commencement of
pneumonitis treatment with incomplete resolution of pneumonitis
changes

was cancer progression on FDG-PET after 5 months
off nivolumab. On discussion between the patient and
her treating team, nivolumab was reinstituted and
treatment continued for a period of 18 months with a
best response of stable disease. No further episodes of
pneumonitis were observed. The patient subsequently
died from cancer-associated venous thromboembolism
unrelated to her prior immunotherapy.
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Case 2: key points—pneumonitis occurring after multiple
cycles of immunotherapy

A 65-year-old Caucasian man was diagnosed with metastatic squamous cell carcinoma of the lung presenting
with a large primary tumor, mediastinal nodal involvement, and a malignant pleural effusion. He was initially
treated with carboplatin and gemcitabine chemotherapy
with partial response. On progression, he was treated
with nivolumab with stable disease as best response. He
had a 47 pack-year smoking history and no other significant medical history. The significant smoking history
and the subsequent risk of developing pneumonitis were
considered, and the decision was made to proceed with
immunotherapy and accept the associated risk given the
potential benefit treatment would provide. He was commenced on nivolumab and was in his seventh month of
treatment at the time of hospital admission. He presented
3 days following administration of nivolumab with dyspnea, productive cough, lethargy, and decreased appetite.
On admission, he was hypoxemic with oxygen saturation of 82% on room air, respiratory rate of 21 breaths
per minute, heart rate of 80 beats per minutes, and temperature of 38.7 °C. His CT chest showed widespread
mixed ground glass and interstitial infiltrate, with progression of his malignancy (Figs. 4, 5). He was treated
with intravenous methylprednisolone 1 g for 5 days.
Mycophenolate was started on the fifth day of admission for a total of 3 days. He received concurrent intravenous antibiotic therapy with cefepime, meropenem,

Fig. 4 Case 2—CT chest upper lobes revealing signs of pneumonitis,
widespread mixed ground glass and interstitial infiltrate. There is
progression of malignancy

Fig. 5 Case 2—CT chest lower lobes revealing signs of pneumonitis,
widespread mixed ground glass and interstitial infiltrate. There is
progression of malignancy

azithromycin, and trimethoprim/sulfamethoxazole. He
continued to deteriorate, with progressively worsening
hypoxemia, and was subsequently transitioned to endof-life care with grade 5 pneumonitis (Figs. 6, 7).

Fig. 6 Case 2—CT chest upper lobes with deterioration of
pneumonitis despite treatment
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Fig. 7 Case 2—CT chest lower lobes with deterioration of
pneumonitis despite treatment

Case 3: key points—early‑onset pneumonitis with rebound
on steroid taper

A 73-year-old Caucasian man with was diagnosed with
T3N1M0 squamous cell carcinoma of the lung. He
received treatment with chemoradiotherapy (weekly
carboplatin/paclitaxel) with curative intent. An early
FDG-PET scan showed partial response, and consolidation immunotherapy durvalumab, a PD-L1 inhibitor,
was commenced. He had a background of emphysema,
cerebellar hematoma, cerebrovascular disease, coronary
artery disease, hyperlipidemia, and hypothyroidism. He
was an ex-smoker with a 75 pack-year history. The significant smoking history, emphysema, and recent radiotherapy were considered as risk factors for the development
of pneumonitis. After consideration, treatment proceeded, given the clear survival benefits demonstrated in
the PACIFIC clinical trial [14]. Six days following the first
dose of durvalumab, he developed dyspnea and a productive cough.
The patient was admitted to hospital. His initial observations showed oxygen saturation was 96% on room air
with a respiratory rate of 20 breaths per minute, temperature of 37 °C, and heart rate of 78 breaths per minute.
His CT scan of the chest showed diffuse peribronchial
ground-glass changes and a decrease in size of the lung
cancer (Figs. 8, 9). He was admitted for 6 days and commenced on oral prednisolone 100 mg with a weaning
regime and concurrent doxycycline for grade 3 pneumonitis. The patient improved clinically, his observations
were within normal cardiorespiratory parameters, and he
was discharged on a prolonged steroid taper. The patient
was reviewed by his respiratory physician and medical
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Fig. 8 Case 3—CT chest before immunotherapy commenced

oncologist in clinic 3 weeks after discharge from hospital. Immunotherapy was not recommenced. A repeat
CT scan showed marked resolution of the ground-glass
changes, and he had returned to his premorbid function
(Fig. 10).
One week after clinic review, the patient was readmitted to hospital with increasing dyspnea and hemoptysis.
He had been on corticosteroids for a period of 4 weeks
and 4 days at this time. He was hypoxemic at 92% oxygen
saturation on 4 L of oxygen per minute via nasal prongs,

Fig. 9 Case 3—CT chest after immunotherapy given revealing signs
of pneumonitis, diffuse peribronchial ground-glass changes. There is
decrease in size of lung cancer
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to Intensive Care Unit (ICU). Immunosuppression was
increased to pulse methylprednisolone 1 g daily with
subsequent administration of intravenous cyclophosphamide. Broad antimicrobial therapy was administered
to cover for concurrent infection (including ceftriaxone,
piperacillin–tazobactam, meropenem, trimethoprim/sulfamethoxazole, and azithromycin over the period of his
admission). Respiratory support included supplemental
oxygen via high-flow nasal prongs and periodic noninvasive ventilation. Intubation and mechanical ventilation
were deemed inappropriate in view of the guarded prognosis and in discussion with the patient and his family.
Despite maximal therapy, the patient’s condition deteriorated, and he died from grade 5 pneumonitis 18 days following admission.

Fig. 10 Case 3—CT chest after treatment of pneumonitis with initial
recovery

Fig. 11 Case 3—CT chest after relapse of pneumonitis. There is no
change in size of lung cancer

had a respiratory rate of 20 breaths per minute and heart
rate of 95 beats per minute, and was afebrile. A repeat CT
scan of the chest showed recurrence of diffuse groundglass infiltrates, in keeping with acute pneumonitis, and
no change in the size of the lung cancer (Fig. 11).
On readmission, oral corticosteroids were reescalated to prednisolone 100 mg. The patient rapidly deteriorated, with worsening hypoxemia requiring admission

Discussion and conclusion
Checkpoint inhibitor immunotherapy now enjoys widespread use in cancer care. Severe adverse events with single-agent PD-1 or PD-L1 inhibition are uncommon but
well described—they can be unpredictable with regard to
timing and severity and can result in significant morbidity and, occasionally, mortality. With any presentation,
irAEs must be considered in the differential diagnosis
and acted on promptly. Pneumonitis remains a toxicity
of particular concern for clinicians treating NSCLC with
greatest incidence of immunotherapy-induced pneumonitis [2]. In the current context, Coronavirus 19 infection
also remains an important differential, and in jurisdictions with community transmission, it is particularly
important to exclude this diagnosis urgently.
The first case highlights that immunotherapy rechallenge is possible but must occur after consideration of
the therapeutic options and a discussion on risks and
benefits. It is important for clinicians to highlight the
uncertainty about the risk of further episodes of irAEs on
immunotherapy rechallenge.
Our case series demonstrates:
1. Patients with underlying lung pathology or smoking history are susceptible to developing high-grade
pneumonitis.
2. Immunotherapy-induced pneumonitis can present at
any time after commencement of immunotherapy.
3. The severity of immunotherapy-induced pneumonitis does not appear to be correlated with the timeframe of onset.
4. Immunotherapy-induced pneumonitis can flare or
recur during the period of steroid taper.
5. Following careful consideration, immunotherapy
rechallenge can occur for some patients with prior
immunotherapy-induced pneumonitis. A careful discussion of the potential risks and benefits is required
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with the patient, given the uncertainty about the risk
of further episodes of irAEs on immunity rechallenge.
Nishinu et al. identified that pneumonitis more commonly occurs in patients who have NSCLC 4.1% and
renal cell carcinoma 4.1%, compared with patients with
metastatic melanoma 1.6% [1]. Similarly, a meta-analysis
of 16 randomized controlled trials found that the lowest rates of pneumonitis were seen in patients treated
for advanced melanoma (0.72%) and highest in patients
treated for advanced NSCLC 4.7% [2]. Patients with
NSCLC are more likely to have underlying lung disease
such as chronic obstructive pulmonary disease (COPD),
potentially increasing their susceptibility to pneumonitis and/or to developing higher-grade pneumonitis [12].
A recent study by Suzuki et al. [15] indicates that lower
lung static volumes such as with large thoracic tumors
are associated with higher pneumonitis risk post-immunotherapy [16]. A past or current smoking history may
also be a risk factor for the development of severe pneumonitis. Whether this is due to smoking itself or due to
smoking-related lung diseases is unclear and perhaps difficult to discern, with two studies showing smoking on
its own was not associated with an increased risk or incidence of pneumonitis [17, 18].
Pneumonitis was demonstrated in this case series to
present at variable time frames following administration of immunotherapy. The onset of pneumonitis from
time of administration of immunotherapy can be variable, which can complicate and delay the diagnosis [19].
In a study by Nishino et al., the median time to onset of
immunotherapy-induced pneumonitis was 2.6 months,
ranging from 0.5 to 11.5 months [13]. Pneumonitis
must be considered among the differential diagnosis for
patients presenting with early clinical deterioration and
respiratory symptoms early in their treatment course.
However, late onset of irAEs including pneumonitis can
occur more than 90 days after cessation of immunotherapy [20]. Delaunay et al. [9] found that the time to onset
of pneumonitis was shorter in patients with NSCLC compared with melanoma, with a median time to onset of
2.1 and 5.2 months, respectively. In the same study, they
found that the time to onset and severity of pneumonitis
appeared to have no correlation [9]. As pneumonitis has
a widely variable and unpredictable onset, pneumonitis
must be carefully considered in the differential diagnosis
of any patient who has received immunotherapy presenting with dyspnea, hypoxia, and/or cough, regardless of
the time of onset.
Management of pneumonitis is based on the grade
attributed by clinicians using the CTCAE definitions
[19]. Treatment options include observation, oral or
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intravenous corticosteroids, cessation of immunotherapy,
and, in refractory cases, the use of immunosuppression
drugs including mycophenolate, infliximab, and cyclophosphamide [11, 13]. Patients may require admission to
hospital and respiratory support in a high-dependency or
intensive care unit. The outcome of patients who develop
pneumonitis can range from complete resolution to
relapse, palliation, or death and is dependent on a multitude of variables [12, 13]. The mainstay of therapy is corticosteroids; however, steroid-refractory cases challenge
clinicians’ decisions regarding the appropriate dose, timing, and route of administration [19]. Steroid-sparing
agents are often employed in the case of steroid refractoriness; however, there appears to be limited data on the
efficacy of these treatments [11]. The length of treatment
and weaning regime implemented can also be a challenge with rebound toxicity on withdrawal of steroids
[19]. As per the European Society for Medical Oncology
guidelines, prednisolone should be weaned over 6 weeks
minimum in grade 2 pneumonitis or minimum 8 weeks
in grade 3 or 4 pneumonitis to prevent rebound of pneumonitis symptoms. However, despite a prolonged weaning regime of immunosuppression following an episode
of pneumonitis, pneumonitis may relapse without further exposure to immunotherapy, with cases of chronic
immune checkpoint pneumonitis as described by Naidoo
et al. [21]. This highlights that the biological effects of
immunotherapy can persist for a long time, and relapse
may occur following a prolonged wean.
The clinical decision to rechallenge with immunotherapy is difficult and needs to be considered on an individual basis. Invariably, the use of immunotherapy agents
is currently occurring in the setting of advanced disease
where the goal of prolonged cancer control is associated
with improved survival. The mortality associated with
the progression of cancer must be weighed up against
the potentially life-threatening irAEs, and this can be a
challenge for physicians with limited data available. The
decision of whether to rechallenge with immunotherapy
following high-grade toxicity is challenging for clinicians
and patients. In general, it has been suggested that redevelopment of irAE after rechallenge is more common in
patients with higher-grade irAE (grade 3 or 4). Santini
et al. [22] recommend avoiding rechallenging patients
who required hospitalization for their initial irAE, as
the recurrence/new rate of irAE’s was up to 87% in these
patients. Interestingly, in a study of 93 patients who were
rechallenged with immunotherapy for a range of different
irAEs, the recurrence of new irAE was not more severe
than the original event [23].
We believe that this case series has provided further
insight into the presentation and risk factors for pneumonitis in patients with NSCLC. Each of the cases of
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immunotherapy-induced pneumonitis illustrates the
different potential patterns that may arise when immunotherapy-induced pneumonitis develops. Given the variable onset and severity of pneumonitis, we recommend
that immunotherapy-induced pneumonitis must always
be considered as a differential, regardless of the time of
onset. Special consideration should be given to patients
with underlying lung disease or a significant smoking history, given the higher risk of mortality. The decision to
rechallenge patients, while difficult, is possible. Early initiation and perhaps prolonged immunosuppressive therapy may be required to optimize patient outcomes.
Abbreviations
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